MEDTECH MOVER (NASDAQ:ACON): Delivering AI-Driven Platform for Managing Lower Back Pain

Aclarion, Inc. (NASDAQ: ACON) is leading a market disruption in the management of lower back pain. Using cutting-edge AI and imaging technology, Aclarion aims to improve clinical outcomes for millions of people suffering from chronic lower back pain worldwide.

WHY PUT ACON ON YOUR WATCHLIST?  

ADDRESSING A MAJOR HEALTHCARE COST: Lower back pain is one of the largest healthcare expenditures in the U.S., with the market for lumbar spine diagnostics and treatment estimated at $40 billion annually and overall costs reaching up to $134.5 billion. Aclarion’s NOCISCAN technology addresses this growing need by offering a noninvasive diagnostic alternative.

FIRST-OF-ITS-KIND NONINVASIVE PLATFORM: Aclarion’s NOCISCAN is the industry’s first noninvasive technology with strong clinical evidence supporting its value. This revolutionary technology has the potential to replace traditional discography and significantly improve surgical outcomes for lower back pain patients.

EXTENSIVE PATENT PORTFOLIO: Aclarion’s platform is backed by 39 issued U.S. and international patents, with another 13 patents pending. This intellectual property supports a broad range of applications, providing the company with a solid foundation for continued growth and expansion.

ESTABLISHED REGULATORY PATHWAYS: Aclarion has secured CPT codes and a clear regulatory path in the U.S., EU, and UK, which paves the way for commercialization and broader adoption of NOCISCAN across key markets.

STRONG MARKET VALIDATION: Aclarion has secured payer coverage from key players like AXA in Greater London, and more recently from Aviva and Vitality in the UK, covering roughly 5.2 million customers. These new partnerships, which began in June 2024, are expected to drive broader adoption of NOCISCAN across London and the UK. In the U.S., the company’s first commercial agreement in Michigan marks its expansion, with two local coverage decisions anticipated in 2025 and a third expected in early 2026.

PROVEN TECHNOLOGY WITH CLINICAL BACKING: Aclarion’s technology has shown promising results. Clinical studies have demonstrated that patients whose NOCISCAN-positive discs were treated saw an 85% improvement. Several clinical trials at various stages are currently underway, with two new trials announced since February 2024, further validating NOCISCAN’s efficacy in both clinical and real-world settings.

LATEST NEWS:

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Key Commercial and Clinical Milestones:

• First Commercial Agreement in Michigan: On August 14, 2024, Aclarion announced its first commercial agreement in Michigan with Sheridan Community Hospital. NOCISCAN is now available in central Michigan, led by neurosurgeon John Keller, MD, making it the first healthcare institution in the state to adopt this innovative technology.
• Contract Extension with The London Clinic: On June 25, 2024, Aclarion extended its commercial agreement with The London Clinic, increasing the price point for NOCISCAN and aligning efforts to secure payer coverage from leading private health insurers. This extension aims to expand access to referring physicians throughout the greater London market.
• Private Payer Coverage in London: Aclarion secured coverage from three of the four largest private insurers in the UK—AXA, Aviva, and Vitality. This represents access to approximately 60% of patients with private health insurance in Greater London, where private insurance accounts for nearly 70% of private hospital revenues. These developments are expected to drive significant growth and broader adoption of NOCISCAN in the UK market.
• CLARITY Trial: Announced in February 2024, the CLARITY trial is a prospective, multi-center, randomized clinical trial designed to validate the superior surgical outcomes associated with NOCISCAN. The trial is expected to enroll up to 300 patients across eight sites, with Johns Hopkins neurosurgeon Nicholas Theodore, MD, serving as the principal investigator. Patient enrollment is expected to begin in Q4 2024, with interim data available by Q1 2026 and full data by Q2 2026.
•  CLUE Trial: On August 21, 2024, Aclarion launched the multi-center Clinical Utility and Economic (CLUE) trial to evaluate how NOCISCAN data influences surgeons’ management plans. The trial will provide real-world data and insights into how NOCISCAN impacts clinical decision-making in chronic low back pain management. Early physician enrollment is underway, with additional sites expected to join in the coming months.

Investing in Aclarion represents an opportunity to be part of a transformative healthcare solution addressing one of the largest and most expensive health conditions globally. With proven technology, strong commercial partnerships, and ongoing clinical validation, Aclarion is poised to deliver significant value for patients, healthcare providers, and investors alike.

Learn more about Aclarion’s growth potential and how you can invest in the future of lower back pain diagnostics.

Sign up to learn more and stay up to date on Aclarion

Aclarion, Inc. does not provide treatments, cures, or medical therapies for any illness or condition. Aclarion’s technology is intended to assist healthcare professionals in identifying potential sources of chronic low back pain. Please consult with a licensed healthcare provider for diagnosis and treatment options.